WO2009109132A1 - 一种药物组合物及其在制备治疗脑血管病药物中的应用 - Google Patents
一种药物组合物及其在制备治疗脑血管病药物中的应用 Download PDFInfo
- Publication number
- WO2009109132A1 WO2009109132A1 PCT/CN2009/070612 CN2009070612W WO2009109132A1 WO 2009109132 A1 WO2009109132 A1 WO 2009109132A1 CN 2009070612 W CN2009070612 W CN 2009070612W WO 2009109132 A1 WO2009109132 A1 WO 2009109132A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- edaravone
- water
- group
- brain
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
Definitions
- the present invention relates to a pharmaceutical composition and its use in the preparation of a medicament for treating cerebrovascular diseases. Background technique
- Cerebrovascular disease is a group of diseases that seriously endanger human health and has become one of the important causes of human disability and death.
- Cerebrovascular disease refers to brain lesions caused by abnormalities in cerebrovascular diseases. Stroke refers to acute cerebrovascular disease.
- Cerebrovascular diseases can be easily divided into two categories, one is ischemic cerebrovascular disease caused by decreased blood flow or interruption, and the other is hemorrhagic cerebrovascular disease caused by rupture of blood vessels.
- Ischemic cerebrovascular disease is mainly cerebral infarction (including cerebral thrombosis and cerebral embolism). In addition to cerebral infarction, there is an ischemic cerebrovascular disease that can be completely recovered within 24 hours without any sequelae.
- TIA transient ischemic attack or transient ischemic attack, doctors are used to refer to TIA for short, also known as small stroke.
- Hemorrhagic cerebral vascular disease is also divided into two categories, one is the rupture of blood vessels, and the blood flows into the brain parenchyma, called cerebral hemorrhage or cerebral hemorrhage. The other type is the rupture of blood vessels.
- the blood flows around the subarachnoid space around the brain, called subarachnoid hemorrhage.
- the doctor is referred to as SAH.
- 3-mercapto-1-phenyl-2-pyrazoline-5-one also known as edaravone, has the structural formula
- 3-mercapto-p-phenyl-2-pyrazol-5-one is a brain protectant that scavenges free radicals and inhibits lipid peroxidation, thereby inhibiting oxidative damage of brain cells, vascular endothelial cells, and nerve cells.
- Intravenous edaravone in rats after ischemia/ischemia reperfusion can prevent the progression of cerebral edema and cerebral infarction, relieve the accompanying neurological symptoms, and inhibit delayed neuronal death.
- the clinical dose of 3-mercapto-1-phenyl-2-pyrazolin-5-one is 60mg/d (mg/day). It has been found to have certain side effects, such as acute renal failure of unknown extent, liver. Adverse reactions such as dysfunction, thrombocytopenia, and disseminated intravascular coagulation.
- the water slice is a commonly used traditional Chinese medicine. It has the functions of “returning to the Soviet Union”, “fragrance to the curtain”, and “taking the medicine up”. It is often used as an “citing drug” to increase the therapeutic effect of other drugs; "Materia Medica” points out The water film "is weak when it is alone, but it is meritorious.” Summary of the invention
- the object of the present invention is to provide a pharmaceutical composition comprising 3-mercapto-1-phenyl-2-pyrazolin-5-one and a water tablet, the pharmaceutical composition having a synergistic effect when used in combination, which can improve the treatment The effect of cerebrovascular disease.
- the weight ratio of 3-mercapto-1-phenyl-2-pyrazoline-5-one to the water tablet is from 4:1 to 1:4, and the preferred weight ratio is from 2:1 to 1:2.
- the water sheet comprises a natural water sheet and a synthetic water sheet, preferably a natural water sheet.
- the natural water tablets can use the natural water tablets contained in the 2005 edition of the Pharmacopoeia of the People's Republic of China, which is the right-handed dragon brain.
- the above pharmaceutical composition may further contain a solvent, which may be a mixture of 3-mercapto-1-phenyl-2-pyrazoline-5-one and a water tablet.
- the solvent may be selected from a water-soluble organic solvent or a mixture of a water-soluble organic solvent and water.
- water-soluble organic solvents are mainly alcohol solvents, ether solvents, ketone solvents, and the like.
- Commonly used alcohol solvents are ethanol, isopropanol, ethylene glycol, propylene glycol, etc.
- commonly used ether solvents are ethylene glycol monoethyl ether, ethylene glycol monobutyl ether, etc.
- commonly used ketone solvents are acetone, N-mercapto-2-pyrrolidone.
- propylene glycol is preferably used as the water-soluble organic solvent.
- Another object of the present invention is to provide an application of the above pharmaceutical composition for the preparation of a medicament for treating cerebrovascular diseases.
- the above pharmaceutical composition is used for the preparation of a medicament for treating ischemic cerebrovascular disease or cerebral infarction.
- the pharmaceutical composition provided by the invention comprises 3-mercapto-1-phenyl-2-pyrazolin-5-one and a water tablet, In the treatment of cerebrovascular diseases, it has a synergistic effect, can significantly increase the therapeutic effect, can reduce the effective dose of 3-mercapto-1-phenyl-2-pyrazolin-5-one, and has low toxicity.
- natural water tablets refers to the natural water tablets contained in the 2005 edition of the Pharmacopoeia of the People's Republic of China, which is the right-handed dragon brain.
- Example 8 Take edara lg, natural water tablets lg, add 200g of propylene glycol solution, stir to completely dissolve, slowly add water for injection and dissolve it to 1000ml, that is.
- Example 1 edaravone injection (2 mg / ml), Example 3 Natural water injection (2 mg/ml), edaravone + natural water injection of Example 5.
- mice were randomly divided into 5 groups, namely sham operation group, model group and drug group. The experimental animals were intraperitoneally injected with the test drug 30 minutes before the ischemia and 12 hours after the reperfusion, and the sham operation group and the model group were injected with the same volume of physiological saline.
- Neurological deficit scores were scored at 24 h after reperfusion according to the Longa 5-point scale.
- the volume of cerebral infarction was measured. After the animal was scored by the last neurological deficit, the brain was decapitated. Excluding the olfactory brain, low brain stem and cerebellum, the remaining part was weighed immediately, and the brain was cut along the coronal surface into five pieces of the same thickness on the water. At 37 ° C, the red tetrazolium dye was bathed for 30 min, normal brain tissue. It is rose red and the infarct area is white. Then, the brain slices were fixed in 10% furfural, and the white tissue was carefully dug and weighed, and the percentage of infarct tissue weight to the total brain weight was used as the infarct volume determination index.
- Brain water content (brain wet weight - brain dry weight) / brain wet weight ⁇ 100.
- the drug group can significantly reduce the infarct volume of cerebral ischemia-reperfusion rats ( ⁇ 0.01); the effect on the symptoms of neurodeficiency in rats, edaravone or natural water tablets have no obvious effect, but The combination of edaravone and natural water tablets significantly improved the symptoms of neurological deficits, suggesting that the two drugs have synergistic or synergistic effects.
- Table 1 Effect on cerebral infarction volume and neurological deficit score after ischemia-reperfusion ( ⁇ s)
- the drug group can significantly reduce the brain water content caused by ischemia-reperfusion.
- the edaravone or natural water tablets alone have significant difference compared with the model group (p ⁇ 0.05), edaravone and natural water tablets are used together. There was a very significant difference (PO.01) compared with the model group, suggesting that the two drugs have synergistic or synergistic effects.
- the results are shown in Table 2.
- the cerebral ischemia-reperfusion model of middle cerebral artery was prepared by internal carotid artery suture. After the animals were anesthetized with 10% hydrated trichloroacetaldehyde (3.5 ml/kg), the prone position was fixed on the operating table, the skin was disinfected, the neck was cut open, and the right common carotid artery, external carotid artery, and internal carotid artery were separated. The vagus nerve was gently dissected, the external carotid artery was ligated and the carotid artery was advanced, and the pterygopalatine artery was ligated.
- MCAO middle cerebral artery
- the proximal common carotid artery was clamped, and the distal end of the ligature line of the external carotid artery was made into a mouth.
- the nylon wire with an outer diameter of 0.285 mm (mm) was inserted into the common carotid artery into the internal carotid artery, and then slowly Inserted until there is slight resistance (about 20mm from the bifurcation), block all blood supply to the middle cerebral artery, monitor cerebral blood flow with laser Doppler cerebral flowmeter, and gently pull the right cerebral ischemia for 2.0h.
- the nylon thread is released, the blood supply is restored, the scalp is sutured, and the scalp is disinfected.
- the surgical group only separated the blood vessels and did not insert a nylon thread.
- the rat's body temperature was maintained at 37.0 ⁇ 0.5 °C throughout the operation using a rat heating plate and a 60 W (watt) table lamp.
- Neurological deficit scores were evaluated using the modified Bederson 5-point method for neurological deficit symptoms. ⁇ Single-blind method was used to evaluate the symptoms of neurological deficits in rats after traumatic brain injury. The animals were labeled by the experimental designer. The testers who scored the symptoms of neurological defects did not know the grouping of the animals. After the score was over, the scorer would The scores of the various markers were submitted to the designer, and the designer was unblinded to obtain a score for each animal of each test group.
- mice were anesthetized with 10% chloral hydrate, decapitated to remove brain, remove olfactory bulb, cerebellum and low brain stem, rinse the blood surface of the brain with saline, and absorb surface residual water, at - 80 Place it at °C for 7 minutes. Immediately after removal, make a coronal section perpendicular to the line of intersection of the line of sight, and cut one piece every 2 mm backward. Place the brain piece freshly in 0.2 mol/L (mol/L) H 7.4 ⁇ 7.8 PBS. The 20 g/L TTC dye solution was bathed in water (37 °C for 90 minutes), the normal brain tissue was stained dark red, and the ischemic brain tissue was pale.
- the brain slices were quickly arranged from front to back.
- absorb the residual water traces on the surface take pictures, separate the left and right brain tissues, and call the brain weight W left (left brain weight) and W right (right brain weight), and add freshly prepared extracts to the left and right brain tissues.
- DMSO dimercaptosulfoxide: 15 ml of ethanol (1:1), protected from light for 24 hours at 25 ° C, fully extracted the red substance formed in the month, until the brain is white.
- Infarct size% 100 X Total area on the right
- Brain damage% 100 ⁇ (1 - ⁇ or so)
- Quantitative data is expressed as mean standard deviation.
- the cerebral infarct size and neurological deficit symptom scores were analyzed by one-way analysis of variance, and Scheffe's test was used to determine the significance of the difference between the two groups.
- the comparison between groups of animal mortality was performed by X 2 test, and the difference PO.05 was defined as significant difference.
- the scores of the severity of neurological symptoms are shown in Table 3.
- the results showed that the combination of edaravone and natural water tablets can significantly improve the symptoms of neurological defects.
- Table 3 Effect of edaravone ( ⁇ ) and natural water tablets ( ⁇ ) on the symptoms of neurological deficits
- the area of cerebral infarction in each group is shown in Table 4.
- the scores of the severity of neurological deficit symptoms are shown in Table 6.
- the results showed that the combination of edaravone and natural water tablets can significantly improve the symptoms of neurological defects.
- Table 6 Effect of edaravone (A) and natural water tablets (B) on the symptoms of neurological deficits
- the area of cerebral infarction in each group is shown in Table 7.
- the damage of each group is shown in Table 8.
- Example 12 Example 13, Example 14, Example 15 Agent; 1, 2-propanediol, 0.9% sodium chloride injection.
- Solvent group 0.9% sodium chloride injection (weight ratio) 10ml/kg solvent group 10ml/kg edaravone 80mg/kg (propylene glycol content 40%)
- Each of the above dose groups calculated the daily dose per rabbit based on the actual body weight of each rabbit, and administered the same volume of the test substance by weight.
- Hematuria During continuous administration of rabbits, edaravone 80, 20mg/kg and compound edaravone 120, 30mg/kg dose and 40% propylene glycol solution 10ml/kg dose appeared after administration. Hematuria, the time of appearance is 30 minutes to 2 hours after administration, and the number of animals appears: edaravone The dose of 80mg/kg is 100%, the dose of edaravone 20mg/kg is 100%, the dose of compound edaravone 120mg/kg is 100%; the dose of compound edaravone 30mg/kg is 50%; 40% propylene glycol The dose of 10 ml / kg of the solution was 100%, while the urine of the 0.9% sodium chloride injection group did not appear.
- Gross view and histopathological examination 1) Gross examination: In the edaravone 80 mg/kg dose group, 3/6 rabbits had a yellowish appearance, swelling, and uneven surface. One of the rabbits had liver necrosis. It is yellowish in color and hard in texture; 3/6 rabbits in the 20 mg/kg dose group have swollen appearance. Compound edaravone 120mg/kg dose of 2/6 rabbits showed mild color and swelling; 30mg/kg dose group and 40% propylene glycol solution 10ml /kg dose showed no obvious appearance changes in rabbit kidney.
- edaravone 80, 20mg/kg and compound edaravone 120, 30mg/kg doses showed different degrees of vascular embolization and other irritative changes in the injection site of rabbits;
- the main damage is renal progressive lesions, such as tubular damage, interstitial inflammatory infiltration and glomerular lesions.
- 40% propylene glycol solution 10ml / kg dose also showed irritative changes such as vascular embolization at the injection site of rabbits, and only mild tubular edema and vacuolar degeneration in rabbit kidney.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09717857A EP2255804B1 (en) | 2008-03-04 | 2009-03-03 | A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases |
JP2010547939A JP5272023B2 (ja) | 2008-03-04 | 2009-03-03 | 薬学的組成物および脳血管疾患の治療用医薬の調製におけるその使用 |
ES09717857T ES2398794T3 (es) | 2008-03-04 | 2009-03-03 | Una composición farmacéutica y la aplicación de la misma en la preparación de una medicina para el tratamiento de enfermedades cerebrovasculares |
CN2009801005279A CN101848711B (zh) | 2008-03-04 | 2009-03-03 | 一种药物组合物及其在制备治疗脑血管病药物中的应用 |
AU2009221546A AU2009221546B2 (en) | 2008-03-04 | 2009-03-03 | A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases |
US12/920,579 US8658684B2 (en) | 2008-03-04 | 2009-03-03 | Pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases |
CA2716874A CA2716874C (en) | 2008-03-04 | 2009-03-03 | A pharmaceutical composition and its use in the preparation of a medicament for the treatment of cerebrovascular diseases |
HK11104441.4A HK1150390A1 (en) | 2008-03-04 | 2011-05-04 | A pharmaceutical composition and the application thereof in the preparation of medicine for the treatment of cerebrovascular diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810020387A CN101524352A (zh) | 2008-03-04 | 2008-03-04 | 一种含有3-甲基-1-苯基-2-吡唑啉-5-酮的组合物 |
CN200810020387.1 | 2008-03-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009109132A1 true WO2009109132A1 (zh) | 2009-09-11 |
Family
ID=41055553
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/070612 WO2009109132A1 (zh) | 2008-03-04 | 2009-03-03 | 一种药物组合物及其在制备治疗脑血管病药物中的应用 |
Country Status (9)
Country | Link |
---|---|
US (1) | US8658684B2 (zh) |
EP (1) | EP2255804B1 (zh) |
JP (1) | JP5272023B2 (zh) |
CN (3) | CN101524352A (zh) |
AU (1) | AU2009221546B2 (zh) |
CA (1) | CA2716874C (zh) |
ES (1) | ES2398794T3 (zh) |
HK (1) | HK1150390A1 (zh) |
WO (1) | WO2009109132A1 (zh) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102920697A (zh) * | 2011-08-12 | 2013-02-13 | 江苏先声药物研究有限公司 | 3-甲基-1-苯基-2-吡唑啉-5-酮与2-莰醇组合物的新用途 |
CN107613976A (zh) * | 2015-06-10 | 2018-01-19 | 江苏先声药业有限公司 | 一种组合物在制备治疗肌萎缩性侧索硬化症药物中的应用 |
RU2693627C2 (ru) * | 2017-11-03 | 2019-07-03 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Комбинации эдаравона для лечения ишемических повреждений мозга |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101732247B (zh) * | 2010-01-06 | 2012-04-25 | 长沙易睿医药科技有限公司 | 一种含有依达拉奉的注射液 |
CN102579432B (zh) * | 2011-01-12 | 2016-05-11 | 江苏先声药物研究有限公司 | 3-甲基-1-苯基-2-吡唑啉-5-酮与2-莰醇组合物的应用 |
CN102648908B (zh) * | 2011-02-26 | 2015-05-20 | 江苏先声药物研究有限公司 | 3-甲基-1-苯基-2-吡唑啉-5-酮与龙脑组合物的应用 |
CN102180832B (zh) * | 2011-03-18 | 2012-09-12 | 苏州沪云肿瘤研究中心有限公司 | 脑缺血保护用化合物及制备方法 |
CN103070861B (zh) * | 2011-10-25 | 2014-12-17 | 江苏先声药物研究有限公司 | 一种药物组合物及其在制备治疗脑血管病药物中的应用 |
CN102526035B (zh) * | 2011-12-08 | 2015-09-30 | 南京优科生物医药研究有限公司 | 一种用于制备抗脑血管疾病药物的组合物 |
CN106727287B (zh) * | 2015-11-23 | 2020-01-24 | 江苏先声药业有限公司 | 依达拉奉和天然冰片的高浓度注射液 |
CN105816423B (zh) * | 2016-03-16 | 2018-07-20 | 福建天泰医药科技有限公司 | 依达拉奉剂型 |
US10494933B2 (en) * | 2016-03-18 | 2019-12-03 | General Electric Company | Airfoil with multi-material reinforcement |
CN107773545A (zh) | 2016-08-29 | 2018-03-09 | 烟台益诺依生物医药科技有限公司 | 依达拉奉与(+)‑2‑莰醇的舌下用药物组合物 |
CN106580966A (zh) * | 2017-01-16 | 2017-04-26 | 江苏先声药业有限公司 | 一种组合物在制备治疗脑震荡的药物中的应用 |
CN108314652A (zh) * | 2017-01-18 | 2018-07-24 | 周意 | 依达拉奉衍生物及其用途 |
CN111346090A (zh) * | 2018-12-22 | 2020-06-30 | 江苏先声药业有限公司 | 一种药物组合物 |
CN112206229A (zh) * | 2019-07-11 | 2021-01-12 | 烟台益诺依生物医药科技有限公司 | 一种组合物在制备治疗脂肪肝、肝炎和肝纤维化中的应用 |
WO2022007833A1 (zh) * | 2020-07-08 | 2022-01-13 | 先声药业有限公司 | 一种组合物在治疗脑卒中的用途 |
WO2022007831A1 (zh) * | 2020-07-08 | 2022-01-13 | 先声药业有限公司 | 一种组合物的医药用途 |
WO2022007832A1 (zh) * | 2020-07-08 | 2022-01-13 | 先声药业有限公司 | 组合物在治疗脑卒中的用途 |
WO2023078325A1 (zh) | 2021-11-08 | 2023-05-11 | 南京宁丹新药技术有限公司 | 一种含有依达拉奉右莰醇组合物在治疗认知障碍中的应用 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1525856A (zh) * | 2001-05-11 | 2004-09-01 | 三菱制药株式会社 | 含吡唑啉酮衍生物的稳定的高浓度注射剂 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK169672B1 (da) | 1985-05-20 | 1995-01-09 | Mitsubishi Chem Ind | Farmaceutiske præparater indeholdende pyrazolonderivater som aktiv bestanddel og anvendelsen af pyrazolonderivater til fremstilling af farmaceutiske præparater |
JPH0725765A (ja) | 1993-07-07 | 1995-01-27 | Mitsubishi Chem Corp | 眼疾患用薬剤 |
JP3758164B2 (ja) | 2000-10-24 | 2006-03-22 | 三菱ウェルファーマ株式会社 | 筋萎縮性側索硬化症(als)治療剤 |
JP2003081830A (ja) | 2001-09-12 | 2003-03-19 | Mitsubishi-Tokyo Pharmaceuticals Inc | 酸化ストレス抑制剤 |
CA2460141C (en) | 2001-09-14 | 2012-01-10 | Mitsubishi Pharma Corporation | Drugs comprising combination of antithrombotic agent with pyrazolone derivative |
JP2004123716A (ja) | 2002-08-06 | 2004-04-22 | Mitsubishi Pharma Corp | 化学物質に起因する肝障害の予防及び/又は治療のための医薬 |
JP2005029573A (ja) | 2003-06-18 | 2005-02-03 | Mitsubishi Pharma Corp | 腫瘍転移抑制剤 |
CN100339085C (zh) * | 2003-09-23 | 2007-09-26 | 天津天士力制药股份有限公司 | 治疗心脑血管疾病的中药组合物 |
WO2005037213A2 (en) | 2003-10-14 | 2005-04-28 | Cornell Research Foundation, Inc. | Antiinflammatory inhibitors of respiratory burst in adherent neutrophils |
AU2003280739A1 (en) | 2003-11-12 | 2004-06-06 | Lead Chemical Co., Ltd. | Percutaneous absorption type cerebral protective agent |
PT1714960T (pt) | 2004-02-09 | 2018-05-02 | Mitsubishi Tanabe Pharma Corp | Um agente terapêutico inovador para a esclerose lateral amiotrófica (ela) ou doenças provocadas pela ela |
CN100450501C (zh) * | 2004-03-17 | 2009-01-14 | 天津天士力制药股份有限公司 | 一种治疗心脑血管疾病的中药制剂及其制备方法 |
CA2576544A1 (en) | 2004-08-10 | 2006-02-16 | Mitsubishi Pharma Corporation | Pyrazolone compounds useful for treatment of cerebrovascular disorders associated with ischemic stroke |
JP4746856B2 (ja) | 2004-08-12 | 2011-08-10 | 三笠製薬株式会社 | ピラゾロン系製剤 |
CN100391489C (zh) * | 2005-12-26 | 2008-06-04 | 深圳市生物谷科技有限公司 | 含有冰片的药物组合物 |
CN100400037C (zh) * | 2006-01-26 | 2008-07-09 | 深圳市生物谷科技有限公司 | 含有冰片、麝香的药物组合物 |
JP2008001607A (ja) | 2006-06-20 | 2008-01-10 | Mitsubishi Pharma Corp | ピラゾロン化合物を含有する水溶液剤 |
JP2008001606A (ja) | 2006-06-20 | 2008-01-10 | Mitsubishi Pharma Corp | ピラゾロン化合物を含有する水溶液剤 |
JP2008001605A (ja) | 2006-06-20 | 2008-01-10 | Mitsubishi Pharma Corp | ピラゾロン化合物を含有する水溶液剤 |
CN101239053A (zh) | 2007-02-06 | 2008-08-13 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | 1,7,7-三甲基二环[2.2.1]庚烷(莰烷、菠烷,樟烷)类似物及其衍生物在治疗氧化损伤神经性疾病中的新用途 |
JP2009143902A (ja) | 2007-11-21 | 2009-07-02 | Kowa Co | エダラボンを含有する安定な水溶性製剤 |
US8784852B2 (en) | 2009-02-27 | 2014-07-22 | Audrey Kunin | Topical skin care composition |
-
2008
- 2008-03-04 CN CN200810020387A patent/CN101524352A/zh active Pending
-
2009
- 2009-03-03 US US12/920,579 patent/US8658684B2/en active Active
- 2009-03-03 WO PCT/CN2009/070612 patent/WO2009109132A1/zh active Application Filing
- 2009-03-03 CA CA2716874A patent/CA2716874C/en active Active
- 2009-03-03 ES ES09717857T patent/ES2398794T3/es active Active
- 2009-03-03 CN CN2012100574524A patent/CN102614171A/zh active Pending
- 2009-03-03 CN CN2009801005279A patent/CN101848711B/zh active Active
- 2009-03-03 EP EP09717857A patent/EP2255804B1/en active Active
- 2009-03-03 JP JP2010547939A patent/JP5272023B2/ja active Active
- 2009-03-03 AU AU2009221546A patent/AU2009221546B2/en active Active
-
2011
- 2011-05-04 HK HK11104441.4A patent/HK1150390A1/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1525856A (zh) * | 2001-05-11 | 2004-09-01 | 三菱制药株式会社 | 含吡唑啉酮衍生物的稳定的高浓度注射剂 |
Non-Patent Citations (3)
Title |
---|
"Pharmacopoeia of People's Republic of China", 2005 |
LIANG, M. ET AL.: "The Effect of Borneol on Evan's Blue Staining of Rabbit and Rat Brain Tissue.", JOURNAL OF GUANGZHOU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE(CHINESE), vol. 10, no. 4, pages 211 - 213 * |
See also references of EP2255804A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102920697A (zh) * | 2011-08-12 | 2013-02-13 | 江苏先声药物研究有限公司 | 3-甲基-1-苯基-2-吡唑啉-5-酮与2-莰醇组合物的新用途 |
CN102920697B (zh) * | 2011-08-12 | 2015-08-19 | 江苏先声药物研究有限公司 | 3-甲基-1-苯基-2-吡唑啉-5-酮与2-莰醇组合物的新用途 |
CN107613976A (zh) * | 2015-06-10 | 2018-01-19 | 江苏先声药业有限公司 | 一种组合物在制备治疗肌萎缩性侧索硬化症药物中的应用 |
CN107613976B (zh) * | 2015-06-10 | 2021-07-06 | 江苏先声药业有限公司 | 一种组合物在制备治疗肌萎缩性侧索硬化症药物中的应用 |
RU2693627C2 (ru) * | 2017-11-03 | 2019-07-03 | Общество С Ограниченной Ответственностью "Валента - Интеллект" | Комбинации эдаравона для лечения ишемических повреждений мозга |
Also Published As
Publication number | Publication date |
---|---|
EP2255804A1 (en) | 2010-12-01 |
CN101848711A (zh) | 2010-09-29 |
JP2011513249A (ja) | 2011-04-28 |
CA2716874C (en) | 2012-12-04 |
ES2398794T3 (es) | 2013-03-21 |
JP5272023B2 (ja) | 2013-08-28 |
CA2716874A1 (en) | 2009-09-11 |
US20110003873A1 (en) | 2011-01-06 |
CN101524352A (zh) | 2009-09-09 |
AU2009221546A1 (en) | 2009-09-11 |
AU2009221546B2 (en) | 2012-07-05 |
US8658684B2 (en) | 2014-02-25 |
EP2255804A4 (en) | 2011-08-03 |
HK1150390A1 (en) | 2011-12-23 |
CN102614171A (zh) | 2012-08-01 |
CN101848711B (zh) | 2012-04-18 |
EP2255804B1 (en) | 2013-01-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2009109132A1 (zh) | 一种药物组合物及其在制备治疗脑血管病药物中的应用 | |
RU2720204C1 (ru) | Сублингвальная фармацевтическая композиция эдаравона и (+)-2-борнеола | |
IL234262A (en) | Pharmaceuticals containing ccr3 inhibitors | |
JP2014185161A (ja) | シロスタゾールを含むカルボスチリル誘導体の脂肪肝治療剤 | |
WO2015051695A1 (zh) | 一种药物组合物在制备治疗脓毒症和炎性肺损伤药物中的应用 | |
JP6889493B2 (ja) | 脳卒中からの回復のための方法および組成物 | |
WO2013189285A1 (zh) | 曲札茋苷在制备改善微循环障碍药物中的应用 | |
CH683965A5 (it) | Composti della classe dei ftalidrazidici come sostanza attiva in agenti antinfiammatori ed antitossici. | |
CN102485223A (zh) | 一种药物组合物及其在制备治疗脑血管病药物中的应用 | |
JP2002534477A (ja) | メラガトランの新規使用 | |
JPS59199630A (ja) | 卵巣機能低下症治療剤 | |
ES2641143T3 (es) | Una composición farmacéutica que comprende palmitoiletanolamida y citidina-difosfocolina | |
KR101067443B1 (ko) | 하이드록시클로로퀸을 함유하는 치핵 치료를 위한 국소투여용 주사제 조성물 | |
JP2022504184A (ja) | ブドウ膜黒色腫の治療のための併用療法 | |
WO2009135432A1 (zh) | 丹酚酸b的抗血栓应用 | |
US20080249034A1 (en) | Use of Macrolides for Treating Intestinal Inflammation | |
CN106880631A (zh) | 一种含有苯并噁嗪吡唑类化合物和冰片的组合物 | |
Wilkinson | A review of drug toxicity in the cat | |
CN112494479B (zh) | 茶黄素在制备卵巢功能保护药物方面的应用 | |
CN108096240B (zh) | 一种治疗肺纤维化的中药组合物 | |
CA2558331A1 (fr) | Utilisation d'un derive du pyrazole, pour la preparation de medicaments utiles dans la prevention et le traitement de la bronchite chronique et de la broncho-pneumopathie chronique obstructive. | |
Kaur et al. | Toxicities and toxicodynamic of anesthetics | |
JP2024503490A (ja) | シロスタゾールを含む組成物の脳血管疾患への応用 | |
JP2007084514A (ja) | 炎症性腸疾患用グリチルリチン製剤 | |
JP2024502662A (ja) | シロスタゾールを含む組成物の脳血管疾患の治療薬の調製への応用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200980100527.9 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09717857 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2716874 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010547939 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009221546 Country of ref document: AU Ref document number: 12920579 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009717857 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2009221546 Country of ref document: AU Date of ref document: 20090303 Kind code of ref document: A |